954112-61-9

Basic information

• Product Name: 5-Chloro-7-azaindole-3-carboxaldehyde
• Synonyms: 5-Chloro-7-azaindole-3-carboxaldehyde;5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde;1H-Pyrrolo[2,3-b]pyridine-3-carboxaldehyde, 5-chloro-;1H-Pyrrolo[2,3-b]pyridine-3-carbaldehyde, 5-chloro-;5-Chloro-7-azaindole-3-carbaldehyde;5-chloro-1H-Pyrrolo[2,3-b]pyridine-3-carboxaldehyde
• CAS NO: 954112-61-9
• Molecular Formula: C8H5ClN2O
• Molecular Weight: 180.594
• Mol File: 954112-61-9.mol
• Article Data: 9

Chemical Properties

• Melting Point: 199-202 °C(Solv: hexane (110-54-3))
• Appearance: /
• Density: 1.521g/cm³
• Refractive Index: 1.748
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.47±0.40(Predicted)
• CAS DataBase Reference: 5-Chloro-7-azaindole-3-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-7-azaindole-3-carboxaldehyde(954112-61-9)
• EPA Substance Registry System: 5-Chloro-7-azaindole-3-carboxaldehyde(954112-61-9)

Safety Data

• Hazardous Substances Data: 954112-61-9(Hazardous Substances Data)

Usage

General Description

5-Chloro-7-azaindole-3-carboxaldehyde is a chemical compound with a molecular formula of C9H6ClN2O. It belongs to the class of azaindole derivatives and is commonly used in the pharmaceutical industry for the synthesis of various drugs and pharmaceuticals. This chemical is known for its versatile reactivity and is often employed as an intermediate in the production of biologically active compounds. Its unique structure and properties make it a valuable building block in organic synthesis, particularly in the development of novel pharmaceuticals. Additionally, 5-Chloro-7-azaindole-3-carboxaldehyde has potential applications in agrochemicals and material science research due to its diverse reactivity and functional groups.

InChI:InChI=1/C8H5ClN2O/c9-6-1-7-5(4-12)2-10-8(7)11-3-6/h1-4H,(H,10,11)

Upstream product

• 866546-07-8 5-chloro-1H-pyrrolo[2,3-b]pyridine 
• 64-19-7 acetic acid 
• 866318-90-3 2-amino-5-chloro-3-[(trimethylsilyl)ethynyl]pyridine 
• 211308-81-5 5-chloro-3-iodo-2-aminopyridine 
• 1072-98-6 5-chloro-2-pyridylamine 
• 100-97-0 hexamethylenetetramine 

Downstream Products

• 954112-81-3 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
• 1029052-73-0 (6-aminopyridin-3-yl)-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methanol 

Relevant articles and documents

Further modifications of 1H-pyrrolo[2,3-b]pyridine derivatives as inhibitors of human neutrophil elastase

Human neutrophil elastase (HNE) is a potent protease that plays an important physiological role in many processes and is considered to be a multifunctional enzyme. HNE is also involved in a variety of pathologies affecting the respiratory system. Thus, compounds able to inhibit HNE proteolytic activity could represent effective therapeutics. We present here a new series of pyrrolo[2,3-b]pyridine derivatives of our previously reported potent HNE inhibitors. Our results show that position 2 of the pyrrolo[2,3-b]pyridine scaffold must be unsubstituted, and modifications of this position resulted in loss of HNE inhibitory activity. Conversely, the introduction of certain substituents at position 5 was tolerated, with retention of HNE inhibitory activity (IC50 = 15–51 nM) after most substitutions, indicating that bulky and/or lipophilic substituents at position 5 probably interact with the large pocket of the enzyme site and allow Michaelis complex formation. The possibility of Michaelis complex formation between Ser195 and the ligand carbonyl group was assessed by molecular docking, and it was found that highly active HNE inhibitors are characterized by geometries favorable for Michaelis complex formation and by relatively short lengths of the proton transfer channel via the catalytic triad.

Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors

Cdc7 is a serine-threonine kinase and plays a conserved and important role in DNA replication, and it has been recognized as a potential anticancer target. Herein, we report the design, synthesis and structure-activity relationship of novel furanone derivatives as Cdc7 kinase inhibitors. Compound 13 was identified as a strong inhibitor of Cdc7 with an IC50 value of 0.6?nM in the presence of 1?mM ATP and showed excellent kinase selectivity. In addition, it exhibited slow off-rate characteristics, which may offer advantages over known Cdc7 inhibitors in its potential to yield prolonged inhibitory effects in?vivo. Compound 13 potently inhibited Cdc7 activity in cancer cells, and effectively induced cell death.

Compounds and methods for kinase modulation, and indications therefor

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereo